GlaxoSmithKline gets green light over Potiga

 

Drugs giant GlaxoSmithKline (up 6.50p at 1283p) and Valeant Pharmaceuticals have won joint approval to sell Potiga, their new epilepsy treatment, in America.

The US Food and Drug administration gave the drug, known generically as ezogabine, the go-ahead but said doctors needed to be informed of various side effects including urinary retention.

The treatment received the green light from EU regulators in March.

Analysts estimate sales of Potiga could range from £122m to £490m.